Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Maruyama H, Miyata K, Mikame M, Taguchi A, Guili C, Shimura M, Murayama K, Inoue T, Yamamoto S, Sugimura K, Tamita K, Kawasaki T, Kajihara J, Onishi A, Sugiyama H, Sakai T, Murata I, Oda T, Toyoda S, Hanawa K, Fujimura T, Ura S, Matsumura M, Takano H, Yamashita S, Matsukura G, Tazawa R, Shiga T, Ebato M, Satoh H, Ishii S. Maruyama H, et al. Among authors: fujimura t. Genet Med. 2019 Aug;21(8):1900. doi: 10.1038/s41436-018-0258-3. Genet Med. 2019. PMID: 30209272 Free PMC article.
Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Maruyama H, Miyata K, Mikame M, Taguchi A, Guili C, Shimura M, Murayama K, Inoue T, Yamamoto S, Sugimura K, Tamita K, Kawasaki T, Kajihara J, Onishi A, Sugiyama H, Sakai T, Murata I, Oda T, Toyoda S, Hanawa K, Fujimura T, Ura S, Matsumura M, Takano H, Yamashita S, Matsukura G, Tazawa R, Shiga T, Ebato M, Satoh H, Ishii S. Maruyama H, et al. Among authors: fujimura t. Genet Med. 2019 Jan;21(1):44-52. doi: 10.1038/gim.2018.31. Epub 2018 Mar 15. Genet Med. 2019. PMID: 29543226 Free PMC article.
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Maruyama H, Miyata K, Mikame M, Taguchi A, Guili C, Shimura M, Murayama K, Inoue T, Yamamoto S, Sugimura K, Tamita K, Kawasaki T, Kajihara J, Onishi A, Sugiyama H, Sakai T, Murata I, Oda T, Toyoda S, Hanawa K, Fujimura T, Ura S, Matsumura M, Takano H, Yamashita S, Matsukura G, Tazawa R, Shiga T, Ebato M, Satoh H, Ishii S. Maruyama H, et al. Among authors: fujimura t. Genet Med. 2019 Feb;21(2):512-515. doi: 10.1038/s41436-018-0125-2. Genet Med. 2019. PMID: 30190610 Free PMC article.
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Maruyama H, Miyata K, Mikame M, Taguchi A, Guili C, Shimura M, Murayama K, Inoue T, Yamamoto S, Sugimura K, Tamita K, Kawasaki T, Kajihara J, Onishi A, Sugiyama H, Sakai T, Murata I, Oda T, Toyoda S, Hanawa K, Fujimura T, Ura S, Matsumura M, Takano H, Yamashita S, Matsukura G, Tazawa R, Shiga T, Ebato M, Satoh H, Ishii S. Maruyama H, et al. Among authors: fujimura t. Genet Med. 2019 May;21(5):1263. doi: 10.1038/s41436-019-0447-8. Genet Med. 2019. PMID: 30728527 Free PMC article.
Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
Hirai Y, Sakurai J, Yoshida S, Kikuchi T, Mitsuhashi T, Miyake T, Fujimura T, Abe R, Fujikawa H, Boki H, Suga H, Shibata S, Miyagaki T, Shimauchi T, Kiyohara E, Kawakami Y, Morizane S. Hirai Y, et al. Among authors: fujimura t. J Dermatol. 2024 Jun 14. doi: 10.1111/1346-8138.17324. Online ahead of print. J Dermatol. 2024. PMID: 38874430
Bexarotene-induced hypothyroidism and dyslipidemia; a nation-wide study.
Manaka K, Sato J, Hikima Y, Horikoshi H, Taguchi M, Morita A, Suga H, Boki H, Fujimura T, Hirai Y, Shimauchi T, Tateishi C, Kiyohara E, Muto I, Nakajima H, Abe R, Fujii K, Nishigori C, Nakano E, Yonekura K, Funakoshi T, Amano M, Miyagaki T, Yamashita R, Sugaya M, Hamada T, Nangaku M, Iiri T, Makita N. Manaka K, et al. Among authors: fujimura t. Endocr J. 2024 Jun 5. doi: 10.1507/endocrj.EJ23-0699. Online ahead of print. Endocr J. 2024. PMID: 38839346 Free article.
Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial.
Fujimura T, Yoshino K, Kato H, Fukushima S, Ishizuki S, Otsuka A, Matsushita S, Amagai R, Muto Y, Yamazaki E, Kambayashi Y, Yahata T, Miyata T, Fujisawa Y, Asano Y. Fujimura T, et al. Br J Dermatol. 2024 Jun 4:ljae231. doi: 10.1093/bjd/ljae231. Online ahead of print. Br J Dermatol. 2024. PMID: 38833158
1,471 results